Advertisement

Combined Treatment with Thiazides and Magnesium in Patients with Recurrent Calcium Oxalate Stone Disease

  • Chr. Ahlstrand
  • H.-G. Tiselius
Conference paper
Part of the Fortschritte der Urologie und Nephrologie book series (2824, volume 22)

Abstract

Thiazides have been extensively used during the last decade to prevent the formation of calcium-containing stones in the urinary tract (Coe 1977; Yendt and Cohanim, 1978). The rationale for this is a reduction in urinary calcium excretion. An increased urinary excretion of magnesium, which may be advantageous in stone prophylaxis, has also been observed (Yendt and Cohanim 1978). However, at least in some patients this effect seems to be transient (Ahlstrand and Tiselius 1981). Furthermore, development of magnesium deficiency during long-term thiazide therapy has been suspected according to observations in patients with cardiac disease (Dyckner and Wester 1978).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ahlstrand, C, Tiselius, H.-G.: Metabolic effects of bendroflumethiazide in patients with recurrent calcium oxalate stone disease. Journal of Urology 126: 635–639 (1981).PubMedGoogle Scholar
  2. 2.
    Coe, F. L.: Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria, or no metabolic disorder. Annals of Internal Medicine 87: 404–410(1977).PubMedGoogle Scholar
  3. 3.
    Dyckner, T., Wester, P. O.: The relations between extra- and intracellular electrolytes in patients with hypokalemia and/or diuretic treatment. Acta Medica Scandinavica 204: 269–282 (1978).PubMedCrossRefGoogle Scholar
  4. 4.
    Greenbaum, B. W., Pace, N.: Determination of citric acid in microliter quantities of urine. Microchemical Journal 15: 673–676 (1970).CrossRefGoogle Scholar
  5. 5.
    Hodgkinson, A. Williams, A.: An improved colorimetric procedure for urine oxalate. Clinica Chimica Acta 36: 127–132 (1972).CrossRefGoogle Scholar
  6. 6.
    Johansson, G., Backman, U., Danielsson, B. G., Fellström, B., Ljunghall, S., Wikström, B.: Biochemical and clinical effects of the prophylactic treatment of renal calcium stones with magnesium hydroxide. Journal of Urology 124: 770–774 (1980).PubMedGoogle Scholar
  7. 7.
    Robertson, W. G., Peacock, M., Nordin, B. E. C: Inhibitors of the growth and aggregation of calcium oxalate in vitro. Clinica Chimica Acta 43: 31–37 (1973).CrossRefGoogle Scholar
  8. 8.
    Tiselius, H.-G., Ahlstrand, C, Larsson, L.: Urine composition in patients with urolithiasis during treatment with magnesium oxide. Urological Research 8: 197–200 (1980).PubMedCrossRefGoogle Scholar
  9. 9.
    Tiselius, H.-G.: An improved method for the routine biochemical evaluation of patients with recurrent calcium oxalate stone disease. Clinica Chimica Acta 122: 409–418 (1982).CrossRefGoogle Scholar
  10. 10.
    Yendt, E. R., Cohanim, M.: Prevention of calcium stones with thiazides. Kidney International 13: 397–409(1978).PubMedCrossRefGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG., Darmstadt 1984

Authors and Affiliations

  • Chr. Ahlstrand
    • 1
  • H.-G. Tiselius
    • 1
  1. 1.Department of UrologyUniversity HospitalLinköpingSweden

Personalised recommendations